Anzeige
Mehr »
Mittwoch, 26.11.2025 - Börsentäglich über 12.000 News
Kupfer-Superzyklus voraus: Dieses Top-Projekt in Nevada wird jetzt zum echten Investmentcase
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DHVP | ISIN: SE0009242555 | Ticker-Symbol: 50V
Frankfurt
26.11.25 | 08:03
0,001 Euro
0,00 % 0,000
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
AINO HEALTH AB Chart 1 Jahr
5-Tage-Chart
AINO HEALTH AB 5-Tage-Chart
GlobeNewswire (Europe)
62 Leser
Artikel bewerten:
(0)

Aino Health AB (publ): Aino Health strengthens growth initiative with SEK 7.7 million in financing from Finnvera and major shareholders

Aino Health Management Oy, wholly owned subsidiary of Aino Health AB, receives significant financing totaling 7,7 million SEK from Finnvera and major shareholders - strengthens growth and international expansion.
Aino Health Management Oy ("Aino Health Management"), has today received a loan from Finnvera Oyj, a state-owned specialized financing company in Finland.

Key terms of the financing:
• Finnvera has granted a loan of EUR 560,000 (approximately SEK 6.2 million).
• The loan carries an annual interest rate of 4,1%.
• The loan will be amortized over 5 years, with the first 12 months being amortization-free.
• In addition, Aino Health Management has received EUR 140,000 (approximately SEK 1.5 million) a subordinated capital loan from the company's four largest owners: Nexit III ky, Tenendum Oy, Jyrki Eklund and Jochen Saxelin. The company's board has approved the terms of the loan and confirms that the terms are on market-based conditions.
• This subordinated capital loan is an equity-type "junior loan" with an annual interest rate of 9%. However, interest cannot be paid, and the loan cannot be amortized except from distributable equity and only after all other loans have been repaid.
• The subordinated capital loan was granted in line with Finnvera's requirement to ensure sufficient owner commitment to the company's development.

Purpose of the financing:
The primary objective of this financing is to strengthen the Aino Groups' capabilities for international expansion and to support the further development of its product offering in selected target markets. The financing enables investments in growth and market entry, strengthening the company's competitiveness internationally.

About Finnvera:
Finnvera Oyj is Finland's state-owned specialized financing company that supplements the financial market by supporting SMEs, exports, and internationalization. It serves as Finland's official Export Credit Agency (ECA), providing loans, guarantees, and export credit guarantees. Finnvera finances its operations through long-term international funding, including its Euro Medium Term Note (EMTN) program, and its obligations are backed by a state guarantee.

For more information
Jyrki Eklund, CEO Aino Health
Phone: +358 40 042 4221
Email: jyrki.eklund@ainohealth.com

Aino Health AB (publ) is listed on Nasdaq Stockholm First North Growth Market (Ticker: AINO).

Certified Adviser
Tapper Partners AB
More info:?https://investors.ainohealth.com/certified-adviser/

This information is information that Aino Health is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-11-26 13:25 CET.

About Aino Health (publ)
Aino Health is the leading provider of Software as a Service (SaaS) solutions for Corporate Health Management. Our platform helps organizations reduce sickness absences, identify root causes of health challenges, and systematize proactive support for employees. For more information, please visit?ainohealth.com.

© 2025 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.